Company Introduction

Management Team

History

Protect Animal Health is founded in 2019 by a group of pet-loving scientist and biotech professionals when they identified the vastly disproportional lag in healthcare development for animals compare to its market growth. Protect leverages over 5 decades of robust human drug development experience to expedite healthcare offerings for the un-met needs in the booming companion pet-care market.

Amongst all, cancer remains one of the biggest unmet-medical need for pets. Many pet patients endure lengthy yet ineffective cancer treatments that makes both pet parents and pet’s limiting time unnecessarily painful. Protect aims to tackle the issue by further developing the noble prize-winning technology, PD-1/PD-L1 immune-checkpoint inhibitor, for pets. PD-1/PD-L1 are validated successes in human cancer treatment, which continues to gain indication coverage until today. Protect is developing a novel therapeutic vaccine to make immunotherapy accessible for pet use.

Protect Animal Health has garnered the support of prominent investors and its team consist of seasoned professionals from institutions and companies such as Harvard, Columbia, Cambridge, Boehringer Ingelheim and Merck to collectively bring forth advanced therapies for companion animals and become a global leader in animal health.

Protector

In Hawaii, pets are known as the Protector. Pets protect not only their closest family member, but also the priceless memories made together. As human healthcare makes incredible leaps, in gene therapy, cell therapy and more, on the other hand, pets are faced with significant lack of proper treatment options, often having to take off-label medicine for human use. Protect searches globally for best healthcare solutions that are truly suitable for pets, particularly in highly prominent age-related disease. From PoC to animal trials, Protect seeks to bring advance healthcare options to market for our beloved pets.

Company Introduction

Protect Animal Health is a Taiwanese life science development company specializing in companion animal care. We are currently developing a novel therapeutic cancer vaccine for companion pet – PT-001. Immunotherapy has been widely proven in the human world, and we at Protect are dedicated to making such advance therapies accessible for our beloved pet children, driving the change for the outdated animal health landscape. Beyond the oncology drug, Protect utilizes our human drug development expertise to tackle unmet-needs in all high potential disease area in pets, also acting as an incubator valuable companion animal drug pipeline. We aim to become the lin pioneering a new standard for animal healthcare.

Operations Team

The operations team has been gradually expanding alongside the product development process. Currently, the team consists of a general manager and department heads overseeing various functions, including administration, research and development (R&D), product development, and finance. These leaders are responsible for managing and driving the tasks and initiatives within their respective departments.

Consultant Team

At Protect Animal Health, our current primary development technol­ogy is licensed from the research team led by Dr. Lan Geng-Li at Taipei Veterans General Hospital. This technology leverages the im­mune checkpoint mechanism, which has been proven effective in human studies, to develop new drugs. By applying the concept of immunotherapy, we aim to shift the current trend of biopharma­ceutical drug development that primarily focuses on monoclonal antibody-based medicines.